CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Summit Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Summit Therapeutics Inc
601 Brickell Key Drive, Suite 1000
Phone: (305) 203-2034p:305 203-2034 MIAMI, FL  33131  United States Ticker: SMMTSMMT
Business Summary
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Co-Chief Executive Officer Robert W.Duggan 79 7/26/2022 12/30/2019
President, Co-Chief Executive Officer, Director MahkamZanganeh 53 7/26/2022 11/11/2020
Chief Financial Officer, Chief Operating Officer, Director Manmeet S.Soni 46 4/2/2024 12/30/2019
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SUMMIT THERAPEUTICS LIMITED 136A EASTERN AVENUE MILTON PARK UK
Discuva Limited The Merrifield Centre Rosemary Lane Cambridge United Kingdom

Business Names
Business Name
Discuva Limited
Discuva Limited
MuOx Limited
19 additional Business Names available in full report.

General Information
Number of Employees: 105 (As of 12/31/2023)
Outstanding Shares: 737,448,146 (As of 10/23/2024)
Shareholders: 178
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024